Gastrointestinal Pathogens Panels Market Size, Share, Growth, and Industry Analysis, Types (Viruses, Bacteria, Parasites), Applications (Hospitals, Diagnostic Laboratories, Point-of-Care, Others), and Regional Insights and Forecast to 2035
Buy Now 
Gastrointestinal Pathogens Panels Market Size
Global Gastrointestinal Pathogens Panels Market size was USD 70.58 Million in 2025 and is projected to touch USD 72.36 Million in 2026, reach USD 74.18 Million in 2027, and grow to USD 90.52 Million by 2035, exhibiting a CAGR of 2.52% during the forecast period from 2026 to 2035. The market is expanding steadily because healthcare systems are increasing adoption of rapid molecular diagnostic technologies for infectious gastrointestinal disease detection. Nearly 48% of healthcare laboratories are focusing on multiplex testing systems to improve diagnostic efficiency and reduce patient waiting time for infection screening results.
The US Gastrointestinal Pathogens Panels Market is showing stable growth due to increasing infectious disease testing demand and expanding molecular laboratory infrastructure. Nearly 54% of hospitals in the United States use multiplex gastrointestinal testing technologies for faster diagnosis and treatment planning. Around 38% of healthcare providers are increasing investments in automated infectious disease testing systems to improve laboratory efficiency and reduce diagnostic turnaround time. Public healthcare awareness programs and foodborne disease surveillance activities are also supporting market demand across the country.
Key Findings
- Market Size: Valued at $70.58 Million in 2025, projected to touch $72.36 Million in 2026, $74.18 Million in 2027, and $90.52 Million by 2035 at a CAGR of 2.52%.
- Growth Drivers: Nearly 58% demand from infectious disease testing, 44% bacterial screening adoption, and 36% increase in molecular diagnostics usage.
- Trends: Around 41% laboratories adopting automated multiplex systems while 29% healthcare providers expand rapid gastrointestinal testing capabilities.
- Key Players: BD, bioMérieux, DiaSorin (Luminex), QIAGEN, Seegene.
- Regional Insights: North America held 38% share, Europe 29%, Asia-Pacific 24%, and Middle East & Africa 9% supported by healthcare modernization.
- Challenges: Nearly 37% laboratories face reimbursement issues while 29% manufacturers manage complex regulatory approval requirements.
- Industry Impact: Around 42% hospitals improved infectious disease diagnosis efficiency while 31% reduced patient diagnostic waiting time significantly.
- Recent Developments: Nearly 24% increase in automated testing investments and 19% improvement in multiplex diagnostic workflow efficiency globally.
The Gastrointestinal Pathogens Panels Market continues to evolve with increasing demand for rapid molecular diagnostics, automated laboratory systems, and improved infectious disease surveillance programs. Healthcare providers are focusing heavily on faster diagnosis, reduced laboratory turnaround times, and broader pathogen detection capabilities. Technological improvements in multiplex gastrointestinal testing systems are helping healthcare facilities improve patient management and infection control efficiency.
Gastrointestinal Pathogens Panels Market Trends
The Gastrointestinal Pathogens Panels Market is seeing stable growth because hospitals and diagnostic laboratories are focusing more on rapid infection detection and accurate gastrointestinal disease diagnosis. Nearly 62% of healthcare providers now prefer multiplex molecular testing methods for gastrointestinal infections because they provide faster results than traditional culture-based testing. Around 48% of laboratories have increased the use of automated pathogen panel systems to improve testing efficiency and reduce manual diagnostic errors. Viral gastrointestinal infections account for nearly 39% of total testing demand, while bacterial infections contribute close to 44% because of rising foodborne disease cases globally. More than 31% of hospitals are adopting point-of-care gastrointestinal pathogen testing to improve emergency care decisions. Around 27% of diagnostic centers are expanding gastrointestinal screening programs due to growing awareness regarding infectious diarrhea and gastrointestinal disease outbreaks. Increasing healthcare infrastructure development and laboratory modernization continue to support the Gastrointestinal Pathogens Panels Market worldwide.
Gastrointestinal Pathogens Panels Market Dynamics
"Expansion of rapid molecular diagnostics"
Nearly 46% of healthcare laboratories are increasing investments in rapid molecular gastrointestinal testing platforms to improve patient diagnosis speed. Around 33% of hospitals are expanding infectious disease screening programs due to increasing gastrointestinal infection cases. The demand for same-day diagnostic testing has increased by almost 29%, creating strong opportunities for gastrointestinal pathogens panel manufacturers and healthcare diagnostic providers.
"Rising demand for infectious disease testing"
Nearly 58% of hospitals are reporting higher gastrointestinal infection screening demand due to increased foodborne illness cases and viral outbreaks. Around 41% of diagnostic laboratories have improved pathogen testing capabilities to support faster treatment decisions. More than 36% of clinicians prefer multiplex gastrointestinal panels because they can identify multiple pathogens through a single testing process.
RESTRAINTS
"Limited accessibility in smaller healthcare facilities"
Nearly 32% of small diagnostic laboratories face difficulties adopting advanced gastrointestinal pathogens panels because of limited laboratory infrastructure and technical expertise. Around 26% of rural healthcare facilities continue using conventional diagnostic methods due to lower equipment availability. High dependence on trained laboratory professionals also affects testing adoption across developing healthcare systems.
CHALLENGE
"Complex regulatory and reimbursement environment"
Nearly 37% of healthcare providers report reimbursement-related issues for multiplex gastrointestinal testing procedures. Around 29% of diagnostic manufacturers face delays in regulatory approvals for advanced pathogen panel systems. More than 24% of laboratories are experiencing operational challenges associated with quality control standards, compliance requirements, and diagnostic accuracy validation.
Segmentation Analysis
The Gastrointestinal Pathogens Panels Market is segmented by type and application based on diagnostic demand, healthcare infrastructure, and infectious disease screening requirements. Increasing gastrointestinal infection cases and rising molecular diagnostic adoption continue to support demand across hospitals, diagnostic laboratories, and point-of-care facilities. Viral and bacterial gastrointestinal testing remains the largest contributor due to increasing infection screening programs globally.
By Type
Viruses
Virus-based gastrointestinal pathogen panels are widely used for detecting norovirus, rotavirus, and adenovirus infections in hospitals and diagnostic laboratories. Nearly 39% of gastrointestinal infection cases tested globally are associated with viral pathogens. Healthcare providers increasingly use rapid viral screening methods to improve infection management and reduce treatment delays during outbreaks.
Viruses segment held a significant share in the Gastrointestinal Pathogens Panels Market, accounting for USD 26.77 Million in 2026, representing nearly 37% of the total market. This segment is expected to grow at a CAGR of 2.4% from 2026 to 2035, supported by increasing viral outbreak monitoring and faster molecular diagnostic adoption.
Bacteria
Bacterial gastrointestinal pathogen panels continue to dominate testing demand due to increasing foodborne bacterial infections and hospital-acquired gastrointestinal illnesses. Nearly 44% of total gastrointestinal diagnostic procedures focus on bacterial detection because of rising salmonella, campylobacter, and E. coli infection cases. Automated bacterial testing systems are becoming increasingly common in modern laboratories.
Bacteria segment accounted for USD 31.12 Million in 2026, representing approximately 43% of the Gastrointestinal Pathogens Panels Market. The segment is projected to grow at a CAGR of 2.8% from 2026 to 2035 because of increasing bacterial infection prevalence and expansion of multiplex testing systems.
Parasites
Parasitic gastrointestinal pathogen panels are gaining attention due to increasing travel-related infections and improved awareness regarding intestinal parasite diagnosis. Around 18% of gastrointestinal testing demand involves parasitic infection screening. Diagnostic laboratories are focusing on improving test sensitivity for protozoa and helminth-related gastrointestinal disease detection.
Parasites segment reached nearly USD 14.47 Million in 2026, accounting for approximately 20% of the market. This segment is expected to grow at a CAGR of 2.1% from 2026 to 2035, driven by increasing global travel and improved gastrointestinal infection surveillance programs.
By Application
Hospitals
Hospitals remain the leading application area in the Gastrointestinal Pathogens Panels Market because of high patient inflow and rising infectious disease screening requirements. Nearly 52% of gastrointestinal pathogen testing procedures are performed in hospitals. Rapid diagnosis helps healthcare professionals reduce infection spread and improve patient treatment decisions.
Hospitals segment accounted for USD 30.39 Million in 2026, representing approximately 42% of the total market. The segment is projected to grow at a CAGR of 2.7% from 2026 to 2035 due to increasing hospitalization rates and growing molecular diagnostic adoption.
Diagnostic Laboratories
Diagnostic laboratories are experiencing strong growth due to increasing outsourcing of infectious disease testing and higher adoption of automated molecular diagnostic systems. Around 38% of gastrointestinal pathogen screening is carried out through specialized laboratories because of advanced testing capabilities and faster turnaround times.
Diagnostic Laboratories segment reached nearly USD 24.60 Million in 2026, representing around 34% of the Gastrointestinal Pathogens Panels Market. This segment is expected to grow at a CAGR of 2.5% from 2026 to 2035 driven by rising laboratory modernization and multiplex testing demand.
Point-of-Care
Point-of-care gastrointestinal testing is becoming more important because healthcare providers need immediate diagnostic results during emergency treatment situations. Nearly 19% of healthcare facilities are increasing adoption of portable molecular testing devices for gastrointestinal infections to improve patient management efficiency.
Point-of-Care segment accounted for USD 10.13 Million in 2026, representing approximately 14% of the market. The segment is expected to grow at a CAGR of 2.9% from 2026 to 2035 because of rising rapid diagnostic adoption and emergency healthcare demand.
Others
Other application areas include academic research institutions and public health laboratories focusing on gastrointestinal disease surveillance and outbreak monitoring. Around 11% of testing demand comes from epidemiological studies and public healthcare screening programs designed to monitor infectious disease spread.
Others segment reached approximately USD 7.24 Million in 2026, accounting for nearly 10% of the Gastrointestinal Pathogens Panels Market. This segment is projected to grow at a CAGR of 2.0% from 2026 to 2035 due to growing public health monitoring activities.
Gastrointestinal Pathogens Panels Market Regional Outlook
The Global Gastrointestinal Pathogens Panels Market size was USD 70.58 Million in 2025 and is projected to touch USD 72.36 Million in 2026, reach USD 74.18 Million in 2027, and grow to USD 90.52 Million by 2035, exhibiting a CAGR of 2.52% during the forecast period from 2026 to 2035. Regional growth is supported by increasing infectious disease testing demand, expansion of molecular diagnostic laboratories, rising gastrointestinal infection cases, and growing awareness regarding rapid multiplex diagnostic technologies across healthcare systems.
North America
North America continues to dominate the Gastrointestinal Pathogens Panels Market because of strong healthcare infrastructure and rapid molecular diagnostic adoption. Nearly 61% of hospitals in the region use multiplex gastrointestinal testing systems for faster infectious disease detection. Around 42% of diagnostic laboratories are increasing automation to improve testing efficiency and reduce manual processing time in gastrointestinal infection screening procedures.
North America held approximately 38% of the Gastrointestinal Pathogens Panels Market in 2026, accounting for nearly USD 27.50 Million of the total market. The region is expected to grow at a CAGR of 2.7% from 2026 to 2035, driven by advanced laboratory infrastructure, rising gastrointestinal disease testing demand, and increased adoption of molecular diagnostics.
Europe
Europe is witnessing stable growth in the Gastrointestinal Pathogens Panels Market due to growing public health screening programs and rising awareness regarding infectious gastrointestinal diseases. Nearly 36% of healthcare laboratories in Europe are investing in rapid molecular testing systems. Around 33% of hospitals are improving infectious disease surveillance to reduce outbreak-related healthcare complications and improve patient outcomes.
Europe accounted for approximately 29% of the Gastrointestinal Pathogens Panels Market in 2026, representing nearly USD 20.98 Million of the total market. The region is projected to grow at a CAGR of 2.4% from 2026 to 2035 supported by rising laboratory modernization and increasing demand for multiplex diagnostic technologies.
Asia-Pacific
Asia-Pacific is experiencing strong demand in the Gastrointestinal Pathogens Panels Market because of expanding healthcare infrastructure and increasing gastrointestinal infection rates. Nearly 47% of healthcare facilities in major urban regions are adopting advanced molecular diagnostic platforms. Around 39% of infectious disease testing demand in the region comes from growing population density and foodborne disease monitoring programs.
Asia-Pacific held approximately 24% of the Gastrointestinal Pathogens Panels Market in 2026, accounting for nearly USD 17.37 Million. The region is expected to grow at a CAGR of 3.0% from 2026 to 2035 due to increasing healthcare investments, expanding diagnostic laboratory networks, and growing infectious disease awareness.
Middle East & Africa
Middle East & Africa is showing moderate growth in the Gastrointestinal Pathogens Panels Market due to increasing investments in diagnostic healthcare services and infectious disease monitoring systems. Nearly 26% of healthcare facilities are upgrading laboratory testing technologies to improve gastrointestinal infection diagnosis. Around 18% of public healthcare programs are focused on improving rapid infectious disease screening capabilities.
Middle East & Africa accounted for approximately 9% of the Gastrointestinal Pathogens Panels Market in 2026, representing nearly USD 6.51 Million of the global market. The region is projected to grow at a CAGR of 2.1% from 2026 to 2035 supported by expanding healthcare access and diagnostic infrastructure improvements.
List of Key Gastrointestinal Pathogens Panels Market Companies Profiled
- BD
- bioMérieux
- DiaSorin (Luminex)
- Quidel
- QIAGEN
- Seegene
- Savyon Diagnostics
- CerTest Biotech
- Anatolia Geneworks
Top Companies with Highest Market Share
- bioMérieux: Holds nearly 21% market share due to strong multiplex testing portfolio and broad hospital laboratory presence.
- QIAGEN: Accounts for approximately 17% market share supported by advanced molecular diagnostic systems and rapid testing adoption.
Investment Analysis and Opportunities in Gastrointestinal Pathogens Panels Market
The Gastrointestinal Pathogens Panels Market is attracting stable investments because healthcare providers are increasingly focusing on rapid infectious disease diagnosis and laboratory automation. Nearly 44% of diagnostic laboratories are investing in multiplex molecular testing systems to improve workflow efficiency and testing accuracy. Around 37% of healthcare organizations are increasing spending on gastrointestinal infection surveillance programs due to rising foodborne disease cases. More than 31% of hospitals are expanding molecular diagnostic capabilities to reduce patient diagnosis time and improve treatment decisions. Investments in point-of-care gastrointestinal testing technologies have increased by nearly 26% because healthcare providers want faster results in emergency settings. Around 34% of market participants are focusing on research activities related to automated sample processing and high-throughput diagnostic systems. Emerging healthcare economies are also creating opportunities for manufacturers because nearly 29% of developing healthcare facilities are upgrading laboratory infrastructure for advanced infectious disease testing.
New Products Development
New product development in the Gastrointestinal Pathogens Panels Market is focused on improving diagnostic accuracy, reducing testing time, and expanding pathogen detection capabilities. Nearly 41% of manufacturers are introducing multiplex testing systems capable of detecting multiple bacterial, viral, and parasitic infections simultaneously. Around 35% of new gastrointestinal diagnostic products are designed with automated workflow features to reduce manual laboratory operations. More than 27% of companies are focusing on portable and compact testing systems suitable for point-of-care applications. Rapid molecular diagnostic kits with simplified sample preparation processes are becoming increasingly popular across hospitals and laboratories. Around 24% of manufacturers are developing high-sensitivity gastrointestinal testing panels with improved detection consistency for infectious disease outbreaks. Healthcare providers are also adopting integrated software systems that improve diagnostic reporting efficiency and support faster clinical decision-making across healthcare facilities.
Recent Developments
- bioMérieux: Expanded multiplex gastrointestinal testing capabilities by nearly 18% to improve pathogen detection efficiency and support high-volume laboratory diagnostic operations globally.
- QIAGEN: Improved molecular testing workflow automation resulting in approximately 21% faster gastrointestinal pathogen result processing within clinical diagnostic laboratories.
- DiaSorin (Luminex): Introduced enhanced gastrointestinal pathogen panel technologies capable of improving detection sensitivity by nearly 16% across multiple infectious disease categories.
- BD: Increased investment in automated infectious disease testing infrastructure by approximately 24% to support rapid gastrointestinal diagnostic expansion across hospital laboratories.
- Seegene: Developed upgraded multiplex testing solutions reducing manual laboratory handling procedures by nearly 19% while improving diagnostic consistency and operational efficiency.
Report Coverage
The Gastrointestinal Pathogens Panels Market report provides detailed analysis of industry trends, molecular diagnostic technologies, healthcare infrastructure development, and infectious disease testing demand. The report covers major pathogen categories including viruses, bacteria, and parasites used in gastrointestinal disease diagnosis. Nearly 44% of total testing demand continues to come from bacterial gastrointestinal infection screening due to rising foodborne illness cases globally.
The report also evaluates application areas such as hospitals, diagnostic laboratories, point-of-care facilities, and public healthcare testing centers. Around 52% of gastrointestinal pathogen testing procedures are currently performed within hospital environments because of high patient volumes and increasing infectious disease screening programs.
Regional analysis within the report includes North America, Europe, Asia-Pacific, and Middle East & Africa. North America remains the leading regional market due to strong molecular diagnostic infrastructure and rising automated laboratory adoption. Nearly 61% of advanced healthcare laboratories in North America use multiplex gastrointestinal testing technologies for rapid infectious disease diagnosis.
The report further highlights market dynamics including growth opportunities, restraints, investment trends, technological advancements, and competitive landscape analysis. Around 36% of diagnostic companies are investing in automated molecular testing systems while nearly 29% are focusing on expanding infectious disease screening programs. The study also includes company profiling, product innovation analysis, healthcare infrastructure trends, and future opportunities associated with rapid gastrointestinal pathogen testing technologies.
Gastrointestinal Pathogens Panels Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 70.58 Million in 2026 |
|
|
Market Size Value By |
USD 90.52 Million by 2035 |
|
|
Growth Rate |
CAGR of 2.52% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation 
Download FREE Sample
|
||
Frequently Asked Questions
-
What value is the Gastrointestinal Pathogens Panels Market expected to touch by 2035?
The global Gastrointestinal Pathogens Panels Market is expected to reach USD 90.52 Million by 2035.
-
What CAGR is the Gastrointestinal Pathogens Panels Market expected to exhibit by 2035?
The Gastrointestinal Pathogens Panels Market is expected to exhibit a CAGR of 2.52% by 2035.
-
Who are the top players in the Gastrointestinal Pathogens Panels Market?
BD, bioMérieux, DiaSorin (Luminex), Quidel, QIAGEN, Seegene, Savyon Diagnostics, CerTest Biotech, Anatolia Geneworks
-
What was the value of the Gastrointestinal Pathogens Panels Market in 2025?
In 2025, the Gastrointestinal Pathogens Panels Market value stood at USD 70.58 Million.
Our Clients
